
Bayer, Astellas gear up for next CEOs; Ex-AMAG chief Scott Myers resurfaces at Viridian
→ You know how we told you last week that we’d keep our eyes peeled for where ex-Roche Pharmaceuticals CEO Bill Anderson turns up next? Well, he gave us an answer in a big way.
Anderson will be the CEO at Bayer starting April 1, the German pharma said Wednesday. Unlike Roche, Merck, J&J and the CEO transition that follows, Bayer chose not to go in-house for Werner Baumann’s replacement. Investors have been grumbling about the company’s stock performance, so much so that activist investor Jeff Ubben rallied the troops to find someone outside the company to take control. In the end, the investors won.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.